{"name":"INmune Bio","slug":"inmune","ticker":"INMB","exchange":"NASDAQ","domain":"inmunebio.com","description":"INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.","hq":"La Jolla, CA","founded":0,"employees":"21","ceo":"Raymond J. Tesi","sector":"Neuroinflammation / Immunology","stockPrice":1.28,"stockChange":0.01,"stockChangePercent":0.79,"marketCap":"$34M","metrics":{"revenue":50000,"revenueGrowth":-91,"grossMargin":100,"rdSpend":33166000,"netIncome":-42082000,"cash":24751000,"dividendYield":0,"peRatio":-1.6,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"XPro patent cliff ($0.00 at risk)","drug":"XPro","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"INmune Bio Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"INmune Bio reported its financial results for the fourth quarter and full year 2023, highlighting progress in its clinical pipeline and operational efficiency.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"INmune Bio Announces Collaboration with University of California, San Diego","summary":"INmune Bio entered into a collaboration with the University of California, San Diego to advance its research in neuroinflammation and immunology.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: ANNUAL REPORT","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-01-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-12-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-12-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-09","type":"pipeline","source":"simplywall.st","summary":"Can INmune Bio (NASDAQ:INMB) Afford To Invest In Growth? - simplywall.st","headline":"Can INmune Bio (NASDAQ:INMB) Afford To Invest In Growth?","sentiment":"neutral"},{"date":"2025-12-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-12-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2025-12-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-26","type":"pipeline","source":"simplywall.st","summary":"INmune Bio's US$7.7m Market Cap Fall Books Insider Losses - simplywall.st","headline":"INmune Bio's US$7.7m Market Cap Fall Books Insider Losses","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOQlJWeUtPSmYzeHlJN2ZrVU5lZXFyb3RBUUxTTmRGNHM2VVc2a3ZPTW9QaW5VU0dicnRQU0FMQlRyY1JRTG9OTUJEQzNhUC05azkxTWptT2NvdzZxNUJqMFh4aUNQOWN6bERtcEtKSVNncGhvem8tNW9wZkc0TEhlT0NESTM1ajF5a0w5UnpDZ21FYXNWa0wzd2tXSm1Ed2o1YkpQWnhlRW1ldjRHWXdWWXB2YUpjeEx0SWFqcElnRnhmc2ZUYTRKbWNnNHRJVEE?oc=5","date":"2025-07-04","type":"pipeline","source":"Sahm","summary":"'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday - Sahm","headline":"'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday","sentiment":"neutral"}],"patents":[{"drugName":"XPro","drugSlug":"tnf-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Roche","Pfizer"],"therapeuticFocus":["Neuroinflammation","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":14000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":14000,"period":"2024-12-31"},{"value":155000,"period":"2023-12-31"},{"value":155000,"period":"2023-12-31"},{"value":374000,"period":"2022-12-31"},{"value":374000,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":33166000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-42082000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":39562000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":21,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.28,"previousClose":1.27,"fiftyTwoWeekHigh":11.64,"fiftyTwoWeekLow":1.09,"fiftyTwoWeekRange":"1.09 - 11.64","fiftyDayAverage":1.37,"twoHundredDayAverage":2,"beta":0.89,"enterpriseValue":10046278,"forwardPE":-1.6,"priceToBook":1.45,"priceToSales":683.24,"enterpriseToRevenue":200.93,"enterpriseToEbitda":-0.33,"pegRatio":0,"ebitda":-30785000,"ebitdaMargin":0,"freeCashflow":-13025125,"operatingCashflow":-22582000,"totalDebt":1034000,"debtToEquity":4.4,"currentRatio":3.55,"returnOnAssets":-53.7,"returnOnEquity":-165.2,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":4,"targetMeanPrice":7,"targetHighPrice":9,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":17,"institutionHeldPercent":18.2,"sharesOutstanding":26585258,"floatShares":20608626,"sharesShort":3256235,"shortRatio":6,"shortPercentOfFloat":12.2,"epsTrailing":-1.94,"epsForward":-0.78,"revenuePerShare":0,"bookValue":0.89,"officers":[{"age":55,"name":"Mr. David J. Moss M.B.A.","title":"President, CEO, Treasurer, Secretary & Director"},{"age":62,"name":"Dr. Mark William Lowdell Ph.D.","title":"Chief Scientific Officer & Chief Manufacturing Officer"},{"age":null,"name":"Mr. Cory Randall Ellspermann","title":"Interim Chief Financial Officer"},{"age":58,"name":"Mr. Daniel Frederick Carlson","title":"Head of Investor Relations"},{"age":null,"name":"Mr. Joshua S. Schoonover Esq.","title":"General Counsel"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.inmunebio.com","phone":"561-710-0512"}}